Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : University Hospital, Lille
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gancyclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : University Hospital, Lille
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Hepatitis B Immunoglobulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Hannover Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins
Details : Hepatect (Human Hepatitis B Immunoglobulin) is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Hepatect
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Human Hepatitis B Immunoglobulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Hannover Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cytofulvin
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : University Hospital, Bordeaux
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cytotect (Cytofulvin) is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Kidney Transplantation.
Product Name : Cytotect
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 22, 2021
Lead Product(s) : Cytofulvin
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : University Hospital, Bordeaux
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Normal Immunoglobulin
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : RWTH Aachen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Human Normal Immunoglobulin is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Peritonitis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 07, 2017
Lead Product(s) : Human Normal Immunoglobulin
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : RWTH Aachen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BT062
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BT062 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 12, 2012
Lead Product(s) : BT062
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
